| Variables |
Raloxifene/experimentalgroups
N=18 |
P- value |
Placebo/controlgroups
N=19 |
P- value |
| Before |
After |
Before |
After |
| BMI(kg/m2) |
30.43 ± 4.15 |
30.56 ± 4.08 |
0.471 |
29.29 ± 4.22 |
29.35 ± 4.32 |
0.76 |
| SBP(mmHg) |
145 ± 15.6 |
135 ± 19.9 |
0.087 |
143.4 ± 19.9 |
134.4 ± 17.9 |
0.13 |
| DBP(mmHg) |
87.2 ± 8.9 |
81 ± 7.5 |
0.036 |
83.8 ± 10.9 |
85.3 ± 10.2 |
0.453 |
| HbA1C(mg/dL) |
7.91 ± 2.54 |
7.86 ± 2.01 |
0.916 |
8.06 ± 1.79 |
7.72 ± 1.68 |
0.47 |
| TG(mg/dL) |
208.5 ± 84.1 |
240.4 ± 98.6 |
0.221 |
167.3 ± 67.5 |
165.1 ± 78.2 |
0.91 |
| Chol(mg/dL) |
209.5 ± 51.7 |
200.6 ± 47.2 |
0.571 |
188.1 ± 43.3 |
186.4 ± 41.7 |
0.79 |
| HDL(mg/dL) |
41.1 ± 5.4 |
40.9 ± 5.1 |
0.884 |
41.3 ± 1.7 |
43.7 ± 6.4 |
0.16 |
| LDL(mg/dL) |
105.4 ± 44.6 |
112.2 ± 44.1 |
0.574 |
111.3 ± 44.8 |
108.8 ± 38.1 |
0.71 |
| ACR Log |
2.4 ± 0.63 |
1.89 ± 0.8 |
0.0091 |
2.16 ± 0.53 |
2.12 ± 0.83 |
0.8 |
| GFR(ml/min) |
68.2 ± 12.9 |
66.3 ± 17.1 |
0.234 |
70.4 ± 32.9 |
69 ± 22.9 |
0.31 |
1-P value< 0.05 is considered statistically significant
BMI: Body Mass Index, SBP: Systolic Blood Pressure, DBP: Diastolic Blood Pressure, TG: Triglyceride, Chol: Cholesterol, HDL: High Density Lipoprotein, LDL: Low Density
Lipoprotein, ACR: Albumin to Creatinin ratio, ACR log: Logarithm of ACR, GFR: Glomerular Filtration Rate |
